Generic entry timeline

Calcium Gluconate generics — when can they launch?

Calcium Gluconate (CALCIUM GLUCONATE) · · 8 active US patents · 0 expired

Earliest patent expiry
2037-07-25
11 years remaining
Full patent estate to
2037-07-25
complete protection through 2037
FDA approval
2017

Where Calcium Gluconate sits in the generic timeline

Long-dated protection: earliest active US patent for Calcium Gluconate extends to 2037 (~11 years out). Generic competition is at least 4 years away. Lifecycle moves (new formulations, label extensions, combination filings) typically execute 18-36 months ahead of cliff.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Formulation — 8 patents

Sample patent estate

Showing 6 of 8 active US patents. View full estate on the Calcium Gluconate drug page →

  • US10342813 Formulation · expires 2037-07-25
    This patent protects a terminally sterilized aqueous calcium gluconate solution packaged in a flexible plastic container with specific weight percentages of calcium gluconate and calcium saccharate.
    USPTO title: Calcium gluconate solutions in flexible containers
  • US10342813 Formulation · expires 2037-07-25
    This patent protects a terminally sterilized aqueous calcium gluconate solution packaged in a flexible plastic container with specific weight percentages of calcium gluconate and calcium saccharate.
    USPTO title: Calcium gluconate solutions in flexible containers
  • US10130646 Formulation · expires 2037-07-25
    This patent protects a terminally sterilized aqueous calcium gluconate solution packaged in a flexible plastic container with specific weight percentages of calcium gluconate and calcium saccharate.
    USPTO title: Calcium gluconate solutions in flexible containers
  • US10342813 Formulation · expires 2037-07-25
    This patent protects a terminally sterilized aqueous calcium gluconate solution packaged in a flexible plastic container with specific weight percentages of calcium gluconate and calcium saccharate.
    USPTO title: Calcium gluconate solutions in flexible containers
  • US10130646 Formulation · expires 2037-07-25
    This patent protects a terminally sterilized aqueous calcium gluconate solution packaged in a flexible plastic container with specific weight percentages of calcium gluconate and calcium saccharate.
    USPTO title: Calcium gluconate solutions in flexible containers
  • US10130646 Formulation · expires 2037-07-25
    This patent protects a terminally sterilized aqueous calcium gluconate solution packaged in a flexible plastic container with specific concentration ranges.
    USPTO title: Calcium gluconate solutions in flexible containers

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on Calcium Gluconate — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →